A Crossover Study of Patients with Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide Vs. Extended Release Torsemide Over 12 Hours After Dosing

The goal of this randomized double-blind crossover study is to assess whether a morning dose of the extended release torsemide has a better efficacy than the ordinary immediate release torsemide to induce renal sodium excretion after a salty lunch in patients with stable heart failure. The main questions it aims to answer are:
* Are the amounts of excreted sodium in the urine during the 2- and 6-hours' time period after a morning dose of extended release torsemide different from the amounts after the immediate release torsemide.
* Are the amounts of excreted sodium in the urine during the 2- and 6-hours' time period after a salty lunch, which will be consumed approximately 6 hours following a morning dose of extended release torsemide, different from the amounts after the immediate release torsemide.
* Is the amount of excreted sodium in the urine during the 24 hours' time period after a salty lunch, which will be consumed approximately 6 hours following a morning dose of extended release torsemide, different from the amount after the immediate release torsemide.
Participants will be asked to:
* Start taking daily immediate release or extended release torsemide tablets that is provided to them.
* Eat the meals with standard contents of sodium that is provided to them and avoid other meals, drinks (except for water) and snacks for the duration of the study.
* Collect urine for 24 hours, after approximately one week of the initiation of the study medication.
* Go to the clinical research center the day that the 24-hour urine collection is finished and stay there throughout the day to receive standard meals and to have blood and urine samples collected.
* Switch torsemide pills to the new one that will be dispensed to them at the clinical research center. If they were taking the immediate release torsemide during the first part, then they will be given the sustained release torsemide and vice versa. The study is double blind; therefore, the subjects, study coordinators, and investigators are unaware of whether each subject is on immediate release torsemide first or on extended release torsemide first.
* Collect urine for an additional 12 hours after leaving the clinical research center to be sent to the clinical research center the next morning.
* Continue to take the provided meals and to avoid other meals, drinks (except for water) and snacks.
* Again, collect urine for 24 hours, after approximately one week, take that to the clinical research center when the 24-hour collection is completed and stay there throughout the day to receive standard meals and to have blood and urine samples collected.
* Collect urine for an additional 12 hours to be sent to the clinical research center the next morning.
Researchers will compare the amount of sodium excretion when each subject is taking immediate release torsemide versus the time that the same subject is taking extended release torsemide.

Start Date15 Nov 2024

Sponsor / Collaborator

Sarfez Pharmaceuticals, Inc.

NCT06708611

/ RecruitingPhase 4

A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients With Heart Failure (EXTOR-HF)

This is a randomized double-blind crossover study of the patients with stable heart failure, who are taking a loop diuretic. During the study period, the participants' loop diuretics will be replaced by the equivalent dose of immediate release/extended release torsemide for one week. After a one week period, they will report to the site and will receive a single dose of either immediate release or extended release Torsemide. The sodium excretion will be measured for six hours after dosing and for an additional six hours after a high salt lunch.

Start Date06 Nov 2024

Sponsor / Collaborator

Sarfez Pharmaceuticals, Inc.

CTRI/2024/09/073919

/ RecruitingPhase 3IIT

Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil

Start Date16 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Torsemide

100 Translational Medicine associated with Torsemide

100 Patents (Medical) associated with Torsemide

1,398

Literatures (Medical) associated with Torsemide

01 Apr 2025·INTERNATIONAL JOURNAL OF CANCER

Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database

Article

Author: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao

Abstract:

Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.

01 Apr 2025·PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Comparative Effectiveness and Safety of Torsemide Versus Furosemide in Older Adults With Heart Failure

Article

Author: Alkhalaf, Amina A. ; Lauffenburger, Julie C. ; Desai, Rishi J.

ABSTRACT:

Purpose:

Evidence on the real‐world comparative effectiveness and safety of commonly used loop diuretics for heart failure is mixed, particularly among older adults who are at a higher risk of adverse outcomes. Thus, we aimed to compare the outcomes and safety profiles of torsemide and furosemide.

Methods:

We conducted a new user, active comparator retrospective cohort study comparing torsemide to furosemide in Medicare fee‐for‐service beneficiaries with heart failure in claims data (2008–2020). Effectiveness outcomes were a composite of heart failure hospitalization or death and urgent outpatient visits requiring intravenous diuretics; safety outcomes included acute kidney injury, hypovolemia, and hypokalemia. We used 1:4 propensity score (PS) matching to adjust for confounding. We calculated PS‐matched hazard ratios using Cox proportional hazard models.

Results:

Across 328 640 matched beneficiaries, compared with furosemide, torsemide was associated with a similar, though statistically significantly lower, risk of the composite effectiveness outcome (hazard ratio [HR] = 0.97, 95% CI:0.95,0.99; incidence rate difference (IRD) = −3.79, 95% CI:‐9.38,1.81 events per 1000 person‐years) and lower risk for urgent visits with intravenous loop diuretics (HR = 0.88, 95% CI:0.84,0.92; IRD = −7.03, 95% CI:‐9.79,−4.26 events per 1000 person‐years). Torsemide was also associated with an increased risk of acute kidney injury (HR = 1.12, 95% CI:1.10,1.15; IRD = 36.89, 95% CI:31.51,42.64 events per 1000 person‐years) with no observed difference in hypokalemia (HR = 1.02, 95% CI:0.91,1.14; IRD = 0.46, 95% CI:−0.51,1.42 events per 1000 person‐years) and hypovolemia (HR = 1.03, 95% CI:0.98,1.09; IRD = 2.36, 95% CI:0.15,4.56 events per 1000 person‐years).

Conclusions:

Compared with furosemide, initiation of torsemide was associated with a slightly lower risk of a composite of all‐cause mortality or heart failure hospitalization and urgent visits with intravenous diuretics, but a slightly higher risk of acute kidney injury. In older adults, clinicians must balance torsemide's potential benefits with the acute kidney injury risk.

01 Mar 2025·JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Torsemide can be used for long-term management of congestive heart failure in equids: a description of 12 cases (2019–2024)

Article

Author: Shroff, Kavita ; Stefanovski, Darko ; Kraus, Marc S. ; Solis, Cristobal Navas de ; Reef, Virginia B.

Abstract:

OBJECTIVE:

Information about congestive heart failure (CHF) treatment in the horse is limited. Torsemide, an oral loop diuretic, is increasingly used in humans, dogs, and cats with CHF. Torsemide is well absorbed and induces diuresis in healthy horses, and its use in a horse with CHF has been reported. This retrospective descriptive study aimed to describe the use of torsemide in equids with CHF.

ANIMALS:

12 equids (10 horses, 1 miniature donkey, and 1 mule).

CLINICAL PRESENTATION:

Horses presented to a referral practice with clinical signs of congestive heart failure. Diagnosis was confirmed with echocardiography. Treatment with torsemide as well as other cardiac medications was instituted. The cases were evaluated and monitored with physical examinations, clinicopathologic data, and repeat echocardiograms.

RESULTS:

Torsemide (PO, q 12 h [median 0.5 mg/kg; IQR, 0.5 to 0.5 mg/kg; range, 0.25 to 1 mg/kg]) was well tolerated in the 12 cases. There were improvements in heart rate and respiratory rate and increases in plasma creatinine concentration (median, 1.3 vs 1.9 mg/dL) that followed therapeutic interventions that included torsemide. Median survival time of equids with CHF treated with torsemide was 189 days (IQR, 10 to 348.25 days; range, 2 to 806 days), with 2 distinct clusters. Four cases were euthanized within 2 weeks after starting treatment, while 8 survived longer than 137 days or are currently alive.

CLINICAL RELEVANCE:

Torsemide can be used in equids diagnosed with CHF without serious adverse events and has the potential to be a useful oral diuretic. The nature of the study does not allow us to conclude that torsemide had a causal relationship with clinical progression.

News (Medical) associated with Torsemide

27 Sep 2023

·synapse.patsnap.com

Analysis on the Clinical Research Progress of CYP2C9 Inhibitors

CYP2C9 is a member of the Cytochrome P450 superfamily of enzymes that primarily metabolize drugs in the human body. It predominantly occurs in the liver and intestine. Approximately 16% of clinically used drugs are metabolized through it, including anti-diabetic drugs such as tolbutamide, glibenclamide, and glimepiride; anti-epileptic drugs like phenytoin; anticoagulants such as warfarin, disulfiram, nitrophenylbenzene, and propylbenzene; antihypertensives like losartan and irbesartan; diuretics like torasemide; antidepressants such as amitriptyline and fluoxetine; non-steroidal anti-inflammatory drugs like ibuprofen, celecoxib, meloxicam, piromelate, and fluorobiphenyl; and antineoplastic drugs like cyclophosphamide and oxazaphosphorines. To date, a variety of mutant alleles from CYP2C9*2 to CYP2C9*35 have been discovered in CYP2C9, with wild-type CYP2C9*1 and mutant-types CYP2C9*2 and CYP2C9*3 being the most common. The frequency of CYP2C9*2 and CYP2C9*3 genetic mutations varies significantly among different populations, with the mutation incidence among Caucasians being higher than that of Asians and Africans. Based on the CYP2C9 genotype, individuals can be classified into normal metabolizers, intermediate metabolizers, and slow metabolizers. CYP2C9 Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 24 Sep 2023, there are a total of 8 CYP2C9 drugs worldwide, from 9 organizations, covering 11 indications, and conducting 3 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the current competitive landscape and future development of target CYP2C9 reveals several key findings. Alvogen, Inc., Bayer AG, and Shaanxi Xiangju Pharmaceutical Co. Ltd. are the companies that are growing fastest under the current target, having reached the approved stage of development. These companies have demonstrated significant progress in their R&D efforts. Drugs targeting CYP2C9 have been approved for indications such as dermatomycoses, mycoses, candidiasis, infectious diseases, hyperuricemia, vaginitis, and skin diseases, infectious. This indicates a recognized need for treatments in these therapeutic areas and the potential efficacy of drugs targeting CYP2C9. Small molecule drugs are progressing most rapidly under the current target, suggesting a focus on traditional pharmaceutical compounds. This may be due to the advantages of small molecule drugs in terms of formulation, delivery, and cost-effectiveness. China, the United States, and Japan are the countries/locations developing fastest under the current target. China, in particular, has shown significant progress, indicating the growing capabilities of Chinese pharmaceutical companies in this area. Overall, the analysis suggests a competitive landscape with companies making progress in R&D efforts, drugs being approved for relevant indications, a focus on small molecule drugs, and the involvement of multiple countries in the development of drugs targeting CYP2C9. The future development of target CYP2C9 holds promise for the advancement of treatments in various therapeutic areas. The globally approved CYP2C9 inhibitor on the market: Isoconazole NitrateIsoconazole Nitrate is a small molecule drug that targets the enzyme CYP2C9. It is primarily used in the treatment of infectious diseases, skin and musculoskeletal diseases, and urogenital diseases. The drug is indicated for various conditions including skin diseases, infectious vaginitis, dermatomycoses, candidiasis, and mycoses. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Isoconazole Nitrate has reached the highest phase of development, which is approved globally. The drug received its first approval in June 1982 in Japan. This indicates that Isoconazole Nitrate has been in use for several decades and has gained regulatory approval in multiple countries. As a small molecule drug, Isoconazole Nitrate is likely to have a well-defined chemical structure and can be easily synthesized. It is designed to interact with the CYP2C9 enzyme, which plays a crucial role in drug metabolism. By targeting this enzyme, Isoconazole Nitrate may modulate its activity and potentially provide therapeutic benefits in the treatment of various diseases. The therapeutic areas of infectious diseases, skin and musculoskeletal diseases, and urogenital diseases suggest that Isoconazole Nitrate may have broad-spectrum activity against different types of pathogens. It may be effective against bacterial, fungal, or viral infections that affect the skin, musculoskeletal system, or urogenital tract. The active indications of Isoconazole Nitrate, such as skin diseases, infectious vaginitis, dermatomycoses, candidiasis, and mycoses, further highlight its potential in treating specific conditions within the therapeutic areas mentioned earlier. These indications suggest that Isoconazole Nitrate may be used to treat various skin infections, vaginal infections, and fungal diseases. Overall, Isoconazole Nitrate is an approved small molecule drug that targets the CYP2C9 enzyme. It has been used since 1982 and is indicated for the treatment of infectious diseases, skin and musculoskeletal diseases, and urogenital diseases. Its active indications include skin diseases, infectious vaginitis, dermatomycoses, candidiasis, and mycoses.

30 Nov 2022

·www.biospace.com

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

BELLEVUE, Wash.--(BUSINESS WIRE)-- Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), and Clinical Consultants International LLC (“CCI”), a Novo wholly-owned subsidiary, today announced the signing of a Consulting Agreement (the “Agreement”) with Sarfez Pharmaceuticals, Inc. (“Sarfez”), a pharmaceutical research and development company with an FDA-approved edema treatment for patients with heart failure and renal disease. Dr. Joseph M. Chalil, MD, MBA, FACHE, Chief Medical Officer of Novo, stated, “Over 50% of patients with heart failure have overactive bladder problems adversely impacting their quality of life. The majority of patients with heart failure are prescribed one of three approved loop diuretics; however, patients may be exposed to worsening bladder problems due to dose adjustment risk. FDA-approved SOAANZ is a gentler loop diuretic that induces gradual and sustained diuresis for the patient over a longer period of time. Through its deep network of hospitals, physicians, and independent pharmacies for direct patient sales, CCI and the Novo team will immediately begin collaborating with Sarfez on the marketing and distribution of commercially available SOAANZ.” Sarfez’s FDA-approved, once-a-day novel formulation of loop diuretic torsemide, SOAANZ®, provides a new treatment option for patients suffering from heart failure who experience persistent edema or swelling in the lower limbs and/or abdomen. Studies have shown that SOAANZ® has a longer duration of peak effects without causing excessive urination. SOAANZ® could potentially help patients with underlying bladder sensitivities allowing the patient to skip a loop diuretic dose due to concerns with worsening bladder problems and negative impact on quality of life. About Sarfez Pharmaceuticals Sarfez Pharmaceuticals is headquartered in Vienna, VA. The pharmaceutical research and development company is focused on cardio-renal products and filling the gap at the intersection of clinical specialties that remained siloed and under-appreciated due to ever-increasing specialization in the practice of medicine. The mission of Sarfez is to develop better treatment options for patients with heart and kidney diseases, especially as they relate to a patients’ quality of life, and provide these treatments at reasonable prices while supporting small and local business including independent pharmacies. For more information on Sarfez Pharmaceuticals, please visit . About Clinical Consultants International LLC CCI, a Novo wholly owned subsidiary, was established in 2006 in Michigan as a local hospital consulting firm. Today, CCI is a global consulting firm specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing, and strategic planning, health policy, and medical device sectors. Headquartered in Boca Raton, Florida, CCI leverages 30+ years of industry experience and its expert consultants worldwide to support clients. For more information on CCI, please visit . About Novo Integrated Sciences, Inc. Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, diagnostic and therapeutic solutions, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner, thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral-based healthcare services, including the patient’s home. Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and, ultimately, a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms. For more information concerning Novo Integrated Sciences, please visit . For more information on Novo Healthnet Limited, Novo’s wholly owned subsidiary, please visit . Twitter, LinkedIn, Facebook, Instagram, YouTube Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts included in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by words such as "believe," “intend,” "expect," "anticipate," "plan," "potential," "continue," or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks, and uncertainties are discussed in Novo’s filings with the Securities and Exchange Commission. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond Novo’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Novo’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Novo assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The contents of any website referenced in this press release are not incorporated by reference herein.

Drug Approval

100 Deals associated with Torsemide

External Link

KEGG	Wiki	ATC	Drug Bank
D00382	Torsemide	C03CA04	DB00214

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Edema, Cardiac	Japan	Mitsubishi Tanabe Pharma Corp.	12 Mar 1999
Hypertension	United States	NORVIUM BIOSCIENCE	09 Sep 1997
Edema	United States	NORVIUM BIOSCIENCE	23 Aug 1993
Edema	United States	Hoffmann-La Roche, Inc.	23 Aug 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic congestive heart failure	Phase 2	United States	Sarfez Pharmaceuticals, Inc.	15 Jun 2024
Urinary Bladder, Overactive	Phase 2	United States	Sarfez Pharmaceuticals, Inc.	15 Jun 2024
Urinary Incontinence	Phase 2	United States	Sarfez Pharmaceuticals, Inc.	15 Jun 2024
Chronic Kidney Diseases	Phase 1	India	Sarfez Pharmaceuticals, Inc.	19 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05093621 (TFO, CTgov)	Phase 3	Heart Failure	47	Furosemide (Furosemide)	zhbyinqvqr = nondyopctf nbdrmacveh (ibufufgblx, vuhafdnnxo - cdynbgardn) View more	-	15 Oct 2024
				Torsemide (Torsemide)	zhbyinqvqr = ckjllsfskc nbdrmacveh (ibufufgblx, rhemvwlsxr - hherjmbxqp) View more
NCT05093621 \| NCT03296813 (TRANSFORM-HF \| TFO, Pubmed \| J Am Soc Nephrol)	Phase 3	Hydrops Fetalis \| Heart Failure	88	Torsemide	ejeireypvq(ibtopqjkuj) = ihuiyefjfe bqknmmcjzf (zcvukjlqkf, 12.3% - 23.5%)	Negative	28 Aug 2024
				Furosemide	ejeireypvq(ibtopqjkuj) = qzzcebhfdk bqknmmcjzf (zcvukjlqkf, 16.6% - 34.1%)
NCT03296813 (TRANSFORM-HF, Pubmed \| Eur J Heart Fail) Manual	Phase 3	Heart Failure	2,570	Torsemide	fzqfqmqhxg(wkmhygwidv) = syzkwjqint mxgmuxeudn (hmehnjicrg ) View more	Negative	15 May 2024
				Furosemide	fzqfqmqhxg(wkmhygwidv) = vrqjxdyetk mxgmuxeudn (hmehnjicrg ) View more
ESC2024	Not Applicable	Heart Failure	-	Torasemide	cdffjzavhb(glyoliytqt) = low blood pressure vjmtrqqqsj (euepkmdhpm ) View more	-	13 May 2024
NCT02813551 (TROPHY, CTgov)	Phase 2	Preeclamptic Toxemia	118	Torsemide (Torsemide)	iipjysihyc = ssevmvwcab xfxjpqjqom (sexecyrhca, uynyxmqnun - fehkfwqoqd) View more	-	10 Apr 2019
				Placebo (Placebo)	iipjysihyc = kuccvcxqzo xfxjpqjqom (sexecyrhca, vnccxscrni - dxksesgmnu) View more
Heart Failure Registries of the European Society of Cardiology (ESC2017)	Not Applicable	Heart Failure	-	Torasemide	udukhfvoer(aqhowmiuvk) = ozvbkmboma pbafuoxzvo (rmjnamvowo )	-	29 Aug 2017
				Furosemide	udukhfvoer(aqhowmiuvk) = nlzknlwogo pbafuoxzvo (rmjnamvowo )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Torsemide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation